AstraZeneca Targets 2025 For First Dublin Manufacturing Site

Pack of pills and drugs
Astrazeneca Is To Open Its First Production Facility In Dublin By 2025.

Anglo-Swedish group AstraZeneca plans to have its first manufacturing base in Ireland operational in Dublin by 2025 in a further boost to the country’s life sciences sector.

Companies like Hines and Harrison Street are targeting Dublin as a city with the potential to develop new life sciences real estate.

AstraZeneca announced plans last year for the construction of its first manufacturing plant in Ireland, with a $360M investment that AstraZeneca Executive Vice President, Operations and IT Pam Cheng said will provide the business with future supply chain flexibility.

While the pharma giant has had a long-term marketing presence in the Irish market, it has not previously manufactured in the country.

However, with the €39.5B deal to acquire U.S. company Alexion in 2020, it bought into a company that has invested more than €600M at sites in Dublin’s College Park in Blanchardstown and Athlone.

“As a result of Alexion joining AstraZeneca, Ireland is becoming really a strategic hub for AstraZeneca,” Cheng told the Irish Times.

The design of the new plant is still subject to planning approval but initially AstraZeneca plans to have the capacity on-site for the development and early stage commercialisation of three drugs simultaneously.

Alongside further investment in Alexion’s Irish sites, the project will bring the group’s investment in Ireland to more than €1.2B to date, and Cheng said that she is confident of delivering the site for regulatory clearance and operations by early 2025.

The facility will feature the latest in digitally enabled production and will be “quite unique and innovative” according to the company.

Cheng said that while development of new medicines normally starts in a “small-scale, lab-heavy” development facility before transferring to commercial-scale manufacture, the Dublin facility will house both development and commercialisation.

This will allow the company to focus on speed of delivery for a new medicine and, once established commercially, it will be transferred to another site, with the Dublin space freed for other pipeline products.

The building’s modular design will enable expansion of production lines to produce additional drugs if needed.

Continue reading this story with a free account

Log in or register
Sign up for more articles like this
Subscribe to Bisnow's Dublin Newsletters
Related Stories

Housing Completions Close To 40,000 As LDA Adds Major Site And CEO Departs

Gwinnett Mall Project Stands To Benefit From Georgia's Opportunity Zone Picks

Deutsche Bank's Asset Manager Needs To Sell To Meet Redemptions. Here's What It Owns

Why Research Triangle Park Life Sciences Is Turning Toward Manufacturing And Flexible Spaces

Ackman-Ziff Leverages National Reach And Boutique Approach To Navigate CRE Markets

Capital Flooded Into Bay Area Apartments. Then Treasury Yields Spiked

Alexandria Sells Stakes In Megacampuses To Weather Life Sciences Downturn

AI Safety Nonprofit Takes 82K SF At BlackRock's King's Cross Campus

JLL Sues Ex-Life Sciences Leader, Alleging Breach Of Noncompete

Journey Outside Dublin Prompts New Growth Phase For Ireland's Data Centres

Ireland's Top Resi Developers Plead For Stability After Regulation Roulette

Bouwinvest, Tishman Speyer Launch U.S. Office Venture With Chrysler Building As Debut Deal